Long-Term Oncological Outcomes after Nerve-Sparing Robot-Assisted Radical Prostatectomy for High-Risk Localized Prostate Cancer: A Single-Center, Two-Arm Prospective Study.

nerve sparing oncologic outcomes prostate cancer robot assisted radical prostatectomy

Journal

Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402

Informations de publication

Date de publication:
11 Apr 2024
Historique:
received: 18 01 2024
revised: 02 04 2024
accepted: 08 04 2024
medline: 26 4 2024
pubmed: 26 4 2024
entrez: 26 4 2024
Statut: epublish

Résumé

To compare the oncological outcomes of patients with high-risk localized prostate cancer undergoing nerve-sparing and non-nerve-sparing robot-assisted radical prostatectomy (RARP). Between November 2002 and December 2018, we prospectively recorded the data of patients undergoing RARP for high-risk localized prostate cancer (PCa) at our tertiary referral center. NSS (nerve-sparing surgery) was carefully offered on the basis of the preoperative clinical characteristics of the patients and an intraoperative assessment. The patients were stratified into two groups: nerve-sparing and non-nerve-sparing groups (yes/no). Radical prostatectomies were performed by 10 surgeons with a robot-assisted technique using a daVinci A total of 779 patients were included in the study: 429 (55.1%) underwent NSS while 350 (44.9%) underwent non-NSS. After a mean (±SD) follow-up of 192 (±14) months, 328 (42.1%) patients developed BCR; no significant difference was found between the NSS and non-NSS groups (156 vs. 172; NSS does not appear to negatively impact the oncological outcomes of patients with high-risk PCa. Randomized clinical trials are needed to confirm our promising findings.

Identifiants

pubmed: 38667449
pii: diagnostics14080803
doi: 10.3390/diagnostics14080803
pii:
doi:

Types de publication

Journal Article

Langues

eng

Auteurs

Lorenzo Spirito (L)

Urology Unit, Department of Neurosciences, Reproductive Sciences, and Odontostomatology, University of Naples "Federico II", 80138 Naples, Italy.

Francesco Chessa (F)

Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.

Anna Hagman (A)

Department of Urology, Karolinska University Hospital, 171 64 Stockholm, Sweden.
Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden.

Anna Lantz (A)

Department of Urology, Karolinska University Hospital, 171 64 Stockholm, Sweden.
Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden.

Giuseppe Celentano (G)

Mediterranea Clinic Hospital, 80122 Naples, Italy.

Rodolfo Sanchez-Salas (R)

Department of Urology, Karolinska University Hospital, 171 64 Stockholm, Sweden.
Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden.

Roberto La Rocca (R)

Urology Unit, Department of Neurosciences, Reproductive Sciences, and Odontostomatology, University of Naples "Federico II", 80138 Naples, Italy.

Mats Olsson (M)

Department of Urology, Karolinska University Hospital, 171 64 Stockholm, Sweden.
Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden.

Olof Akre (O)

Department of Urology, Karolinska University Hospital, 171 64 Stockholm, Sweden.
Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden.

Vincenzo Mirone (V)

Urology Unit, Department of Neurosciences, Reproductive Sciences, and Odontostomatology, University of Naples "Federico II", 80138 Naples, Italy.

Peter Wiklund (P)

Department of Urology, Karolinska University Hospital, 171 64 Stockholm, Sweden.
Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden.

Classifications MeSH